The impact on blood donor screening for human immunodeficiency virus, hepatitis C virus, and hepatitis B virus using plasma from frozen‐thawed plasma preparation tubes

Allison, Kirsty M; Faddy, Helen M.; Margaritis, Angelo R.; Ismay, S.; Marks, Denese C.

doi:10.1111/trf.13372

Cited by 7 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was confirmed in a recent study by the Australian Red Cross Blood Service [14] showing that the detection of HCV RNA was not affected by storing plasma frozen at -30 ° C for up to 3 years at high and low viral load levels, and that the detection of HCV RNA was not affected by up to three freeze-thaw cycles.…”

Section: Discussionsupporting

confidence: 69%

HCV RNA Testing of Plasma Samples from Cornea Donors: Suitability of Plasma Samples Stored at 4 °C for up to 8 Days

Berger

Salla

Keppler

et al. 2016

Transfus Med Hemother

View full text Add to dashboard Cite

Background: The HCV RNA testing of potential cornea donors frequently relies on blood samples stored pre mortem. The recommended storage time of maximum 72 h frequently excludes a significant fraction of donors. Methods: The influence of storage time of EDTA plasma samples at 4 °C on the viral load measured with the Roche HCV Quantitative Test vs. 2.0 was evaluated for 43 samples from HCV-positive individuals. Results: The mean reduction of the viral load after 4 °C storage for 6-8 days was 0.46 log₁₀ IU/ml (range +0.17 to -1.66 log₁₀ IU/ml). After 1-3 days a mean loss of 0.19 log₁₀ IU/ml (range +0.30 to -1.41 log₁₀ IU/ml) and after 3-5 days of 0.32 log₁₀ IU/ml (range +0.36 to -1.81 log₁₀ IU/ml) was observed. In 23.3% of samples, a viral load reduction ≥ 1 log₁₀ IU/ml (1.0-1.81 log₁₀ IU/ml) was found after prolonged storage (5-8 days). In none of the samples did the HCV load fall below the detection limit. Conclusion: Plasma storage for up to 8 days can quantitatively reduce the HCV RNA load, yet has no influence on the reliability of a qualitative HCV RNA detection by this ultrasensitive test to determine the HCV status of serologically negative cornea donors.

show abstract

Section: Discussionsupporting

confidence: 69%

HCV RNA Testing of Plasma Samples from Cornea Donors: Suitability of Plasma Samples Stored at 4 °C for up to 8 Days

Berger

Salla

Keppler

et al. 2016

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…We tested serum samples after they had been subjected to a freeze/thaw cycle, which could also have potential influence on retrieval of infectious virus. However, as samples were frozen in accordance with standard laboratory operating protocols within a few hours of collection, we anticipate this would have a limited impact on viral replication capacity, as has been demonstrated previously for other viruses [48][49][50] .…”

Section: Caveats and Limitationsmentioning

confidence: 99%

SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus

et al. 2020

View full text Add to dashboard Cite

Background: Laboratory diagnosis of SARS-CoV-2 infection (the cause of COVID-19) uses PCR to detect viral RNA (vRNA) in respiratory samples. SARS-CoV-2 RNA has also been detected in other sample types, but there is limited understanding of the clinical or laboratory significance of its detection in blood. Methods: We undertook a systematic literature review to assimilate the evidence for the frequency of vRNA in blood, and to identify associated clinical characteristics. We performed RT-PCR in serum samples from a UK clinical cohort of acute and convalescent COVID-19 cases (n=212), together with convalescent plasma samples collected by NHS Blood and Transplant (NHSBT) (n=462 additional samples). To determine whether PCR-positive blood samples could pose an infection risk, we attempted virus isolation from a subset of RNA-positive samples. Results: We identified 28 relevant studies, reporting SARS-CoV-2 RNA in 0-76% of blood samples; pooled estimate 10% (95%CI 5-18%). Among serum samples from our clinical cohort, 27/212 (12.7%) had SARS-CoV-2 RNA detected by RT-PCR. RNA detection occurred in samples up to day 20 post symptom onset, and was associated with more severe disease (multivariable odds ratio 7.5). Across all samples collected ≥28 days post symptom onset, 0/494 (0%, 95%CI 0-0.7%) had vRNA detected. Among our PCR-positive samples, cycle threshold (ct) values were high (range 33.5-44.8), suggesting low vRNA copy numbers. PCR-positive sera inoculated into cell culture did not produce any cytopathic effect or yield an increase in detectable SARS-CoV-2 RNA. Conclusions: vRNA was detectable at low viral loads in a minority of serum samples collected in acute infection, but was not associated with infectious SARS-CoV-2 (within the limitations of the assays used). This work helps to inform biosafety precautions for handling blood products from patients with current or previous COVID-19.

show abstract

Section: Caveats and Limitationsmentioning

confidence: 99%

SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus

Andersson¹,

Arancibia‐Cárcamo²,

Auckland³

et al. 2020

Wellcome Open Res

123

View full text Add to dashboard Cite

Background: Laboratory diagnosis of SARS-CoV-2 infection (the cause of COVID-19) uses PCR to detect viral RNA (vRNA) in respiratory samples. SARS-CoV-2 RNA has also been detected in other sample types, but there is limited understanding of the clinical or laboratory significance of its detection in blood. Methods: We undertook a systematic literature review to assimilate the evidence for the frequency of vRNA in blood, and to identify associated clinical characteristics. We performed RT-PCR in serum samples from a UK clinical cohort of acute and convalescent COVID-19 cases (n=212), together with convalescent plasma samples collected by NHS Blood and Transplant (NHSBT) (n=462 additional samples). To determine whether PCR-positive blood samples could pose an infection risk, we attempted virus isolation from a subset of RNA-positive samples. Results: We identified 28 relevant studies, reporting SARS-CoV-2 RNA in 0-76% of blood samples; pooled estimate 10% (95%CI 5-18%). Among serum samples from our clinical cohort, 27/212 (12.7%) had SARS-CoV-2 RNA detected by RT-PCR. RNA detection occurred in samples up to day 20 post symptom onset, and was associated with more severe disease (multivariable odds ratio 7.5). Across all samples collected ≥28 days post symptom onset, 0/494 (0%, 95%CI 0-0.7%) had vRNA detected. Among our PCR-positive samples, cycle threshold (ct) values were high (range 33.5-44.8), suggesting low vRNA copy numbers. PCR-positive sera inoculated into cell culture did not produce any cytopathic effect or yield an increase in detectable SARS-CoV-2 RNA. There was a relationship between RT-PCR negativity and the presence of total SARS-CoV-2 antibody (p=0.02). Conclusions: vRNA was detectable at low viral loads in a minority of serum samples collected in acute infection, but was not associated with infectious SARS-CoV-2 (within the limitations of the assays used). This work helps to inform biosafety precautions for handling blood products from patients with current or previous COVID-19.

show abstract

The impact on blood donor screening for human immunodeficiency virus, hepatitis C virus, and hepatitis B virus using plasma from frozen‐thawed plasma preparation tubes

Cited by 7 publications

References 15 publications

HCV RNA Testing of Plasma Samples from Cornea Donors: Suitability of Plasma Samples Stored at 4 °C for up to 8 Days

HCV RNA Testing of Plasma Samples from Cornea Donors: Suitability of Plasma Samples Stored at 4 °C for up to 8 Days

SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus

SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus

Contact Info

Product

Resources

About